Efficacy and safety of palonosetron for the prophylaxis of chemotherapy-induced nausea and vomiting (CINV): A systematic review and meta-analysis of randomized controlled trials

Supportive Care in Cancer

Volumn 22, Issue 6, 2014, Pages 1685-1697

  Popovic, Marko ^a   Warr, David G ^b   DeAngelis, Carlo ^c   Tsao, May ^a   Chan, Kelvin K W ^c   Poon, Michael ^a   Yip, Cheryl ^a   Pulenzas, Natalie ^a   Lam, Henry ^a   Zhang, Liying ^a   Chow, Edward ^a  

^a DEPARTMENT OF RADIATION ONCOLOGY   (Canada)

^b PRINCESS MARGARET HOSPITAL   (Canada)

^c UNIVERSITY OF TORONTO   (Canada)

Author keywords

Chemotherapy induced nausea and vomiting; Efficacy; Palonosetron; Safety

Indexed keywords

ANTIEMETIC AGENT; ANTINEOPLASTIC AGENT; DEXAMETHASONE; PALONOSETRON; SEROTONIN 3 ANTAGONIST;

ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER PATIENT; CHEMORADIOTHERAPY; CHEMOTHERAPY INDUCED NAUSEA AND VOMITING; CONSTIPATION; DIARRHEA; DIZZINESS; DRUG EFFICACY; DRUG SAFETY; HEADACHE; HUMAN; META ANALYSIS; ONCOLOGY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SENSITIVITY ANALYSIS; SYSTEMATIC REVIEW; TREATMENT OUTCOME;

ANTIEMETICS; ANTINEOPLASTIC AGENTS; HUMANS; ISOQUINOLINES; NAUSEA; QUINUCLIDINES; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SEROTONIN ANTAGONISTS; VOMITING;

EID: 84902333777     PISSN: 09414355     EISSN: 14337339     Source Type: Journal    
DOI: 10.1007/s00520-014-2175-6     Document Type: Review

References (25)

1. Flaherty AM (2013) Historical perspective on the progress of chemotherapy-induced nausea and vomiting treatment in oncology nursing forum. Oncol Nurs Forum 40(3):205-207
2. Feyer P, JordanK(2011) Update and new trends in antiemetic therapy: the continuing need for novel therapies. Ann Oncol 22:30-38
3. Roscoe JA, Heckler CE, Morrow GR et al (2012) Prevention of delayed nausea: a University of Rochester Cancer Center Community Clinical Oncology Program study of patients receiving chemotherapy. J Clin Oncol 30(27):3389-3395
4. Saito M, Aogi K, Sekine I et al (2009) Palonosetron plus dexamethasone versus granisetron plus dexamethasone for prevention of nausea and vomiting during chemotherapy: a double-blind, double-dummy, randomized, comparative phase III trial. Lancet Oncol 10:115-124
5. Gralla R, Lichinitser M, Van der Vegt S et al (2003) Palonosetron improves prevention of chemotherapy-induced nausea and vomiting following moderately emetogenic chemotherapy: results of a double-blind randomized phase III trial comparing single doses of palonosetron with ondansetron. Ann Oncol 14:1570-1577 (Pubitemid 37304615)
6. 3receptor antagonist. Cancer 98(11):2473-2482
7. Aapro MS, Grunberg SM, Manikhas GM et al (2006) A phase III, double-blind, randomized trial of palonosetron compared with ondansetron in preventing chemotherapy-induced nausea and vomiting following highly emetogenic chemotherapy. Ann Oncol 17:1441-1449 (Pubitemid 44400384)
8. Sepulveda-Vildosola AC, Betanzos-Cabrera Y, Lastiri GG et al (2008) Palonosetron hydrochloride is an effective and safe option to prevent chemotherapy-induced nausea and vomiting in children. Arch Med Res 39:601-606 (Pubitemid 352033608)
9. Ghosh S, Dey S (2010) Comparing different antiemetic regimens for chemotherapy induced nausea and vomiting. Int J Collab Res Int Med Pub Health 2(5):142-156
10. Botrel TEA, Clark OAC, Clark L, Paladini L, Faleiros E, Pegoretti B (2011) Efficacy of palonosetron (PAL) compared to other serotonin inhibitors (5-HT3R) in preventing chemotherapy-induced nausea and vomiting (CINV) in patients receiving moderately or highly emetogenic (MoHE) treatment: systematic review and meta-analysis. Support Care Cancer 19:823-832
11. Likun Z, Xiang J, Yi B, Xin D, Tao ZL (2011) A systematic review and meta-analysis of intravenous palonosetron in the prevention of chemotherapy-induced nausea and vomiting in adults. Oncologist 16: 207-216
12. Jin Y, Sun W, Gu D, Yang J, Xu Z, Chen J (2013) Comparative efficacy and safety of palonosetron with the first 5-HT3 receptor antagonists for the chemotherapy-induced nausea and vomiting: a meta analysis. Eur J Cancer Care 22:41-50
13. Roila F, Herrstedt J, Aapro M et al (2010) Guideline update for MASCC and ESMO in the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting: results of the Perugia consensus conference. Ann Oncol 21(Suppl 5):v232-v243
14. Yu Z, Liu W, Wang L et al (2009) The efficacy and safety of palonosetron compared with granisetron in preventing highly emetogenic chemotherapy-induced vomiting in the Chinese cancer patients: a phase II, multicenter, randomized, double-blind, parallel, comparative clinical trial. Support Care Cancer 17:99-102
15. Chen YX, Qin SK, Cheng Y et al (2007) A multicenter, double-blind, randomized control clinical trial of palonosetron hydrochloride injection to prevent chemotherapy-induced nausea and vomiting. Chin Clin Oncol 12:161-165
16. Li ZQ, Xu JM, Liu DQ et al (2009) Phase II trial of hydrochloride in the prevention of moderately to severely emetogenic chemotherapy induced nausea and vomiting. Chin Clin Oncol 14:487-490
17. Dong X, Huang J, Cao R, Liu L (2011) Palonosetron for prevention of acute and delayed nausea and vomiting in non-small-cell lung carcinoma patients. Med Oncol 28:1425-1429
18. Tian W, Wang Z, Zhou J et al (2011) Randomized, double-blind, crossover study of palonosetron compared with granisetron for the prevention of chemotherapy-induced nausea and vomiting in a Chinese population. Med Oncol 28:71-78
19. Mattiuzzi GN, Cortes JE, Blamble DA et al (2010) Daily palonosetron is superior to ondansetron in the prevention of delayed chemotherapy-induced nausea and vomiting in patients with acute myelogenous leukemia. Cancer 116(24):5659-5666
20. Kaushal J, Gupta MC, Kaushal V et al (2010) Clinical evaluation of two antiemetic combinations palonosetron dexamethasone versus ondansetron dexamethasone in chemotherapy of head and neck cancer. Singap Med J 51(11):871-875
21. Wenzell CM, Berger MJ, Blazer MA et al (2013) Pilot study on the efficacy of an ondansetron-versus palonosetron-containing antiemetic regimen prior to highly emetogenic chemotherapy. Support Care Cancer 21(10):2845-2851
22. Huang J, Wang XJ, Yu D et al (2013) The effect of palonosetron hydrochloride in the prevention of chemotherapy-induced moderate and severe nausea and vomiting. Exp Ther Med 5:1418-1426
23. Bernardo G, Palumbo R, Frascaroli M et al (2009) Palonosetron compared to ondansetron in the prevention of chemotherapy-induced nausea and vomiting: activity, safety, and cost-effectiveness evaluation. J Clin Oncol 27:e20573
24. PrAloxi®. Mississauga: Eisai Limited; 2012.
25. Schouten EG, Dekker JM, Meppelink P, Kok FJ, Vandenbroucke JP, Pool J (1991) QT interval prolongation predicts cardiovascular mortality in an apparently healthy population. Circulation 84: 1516-1523